Home  /  Resource Library  /  Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle Cell Lymphoma

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle Cell Lymphoma

Results of a study investigating ibrutinib combined with bendamustine and rituximab for first line treatment of mantle cell lymphoma. (Abstract only)